代红胜 博士

教授，博士生导师

电子邮件:daihsh@outlook.com

通讯地址：广东省广州市白云区沙太南路1023号（510515）

工作经历：

2019年12月起南方医科大学， 基础医学院免疫学教研室，教授， 博士生导师

2018/07-2019/10希望城医学中心 (City of Hope National Medical Center),助理研究教授

2017/11-2018/06俄亥俄州立大学(The Ohio State University， USA),研究科学家

2013/06-2017/10俄亥俄州立大学(The Ohio State University， USA),博士后

教育经历：

2008-2012普渡大学 (Purdue University， USA), 分子病毒学， 博士

2000-2007 南开大学 七年制临床医学 医学本科,硕士

研究方向：

1.新型病毒疫苗

2. NK 细胞功能

3.新型免疫治疗

专利：

1.Passive antibody dependent cell-mediated activation, International application, PCT/US2018/016035；Priority 2017-01-30 • Filing 2018-01-30 • Publication 2018-08-02

Caligiuri Michael（45% royalty）, Dai Hongsheng (45% royalty), Yu Jianhua (10% royalty)

2.IgG antibody compositions and methods of making the same. EFS ID：36968902，Priority 2019-08-23， Caligiuri Michael, Dai hongsheng, Zhang Tongwen

代表性论著:

1. Dai HS*, Griffin N, Bolyard C, Mao C, Zhang J, Cripe T, Suenaga T, Arase H, Nakano I, Chiocca E, Kaur B, Yu J, Caligiuri MA*, The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells.Immunity. 2017 Jul 18;47(1):159-170. PMID: 28723548 PMCID: PMC5568648 (* co-corresponding author),

2.Dai HS* and Caligiuri MA*, Molecular basis for the recognition of HSV1 infection by human NK cells. Frontiers in Immunology 2018.12;9:183.PMID: 29483911 (* co-corresponding author),

3.Dai HS*, Liu Z, Jiang W, Kuhn RJ*. Directed evolution of a virus exclusively utilizing human epidermal growth factor receptor as the entry receptor. J Virol. (2013). Oct;87(20):11231-43. PMID:23926357 PMCID: PMC3807306 (*co-corresponding authors),

4.Xu B, Ma R, Russell L, Yoo JY, Han J, Cui H, Yi P, Zhang J, Nakashima H, Dai HS, Chiocca EA, Kaur B, Caligiuri MA, Yu J. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nat Biotechnol. 2019，37, 45–54. PMID: 30475349，

5.Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai HS, Nallanagulagari T, Wojton J, Hurwitz BS, Relation T, Lee TJ, Lotze MT, Yu JG, Zhang J, Croce CM, Yu J, Caligiuri MA, Old M, Kaur B. (2016).Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy. Clin Cancer Res. Nov 1;22(21):5265-5276. PMID: 28723548 PMCID: PMC5568648,

6.Otani Y, Yoo JY, Chao S, Liu J, Jaime-Ramirez AC, Lee TJ, Hurwitz B, Yan Y, Dai HS, Glorioso JC, Caligiuri MA, Yu J, Kaur B. Oncolytic HSV infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition.Clin Cancer Res. 2020 Mar 5.

代表性课题：

1.南方医科大学第三层次人才科研启动金（300万）

2.P01 CA163205 (MPI : Caligiuri/Chiocca) 02/07/2013 – 01/31/2023 NIH/NCI

Title: Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas

This P01 explores the use of oncolytic virotherapy to cure malignant gliomas. Project 4 deals with the mechanism by which NK cells recognize and eliminate oncolytic herpes virus.

Role: Co-investigator on Project 4 (since 2018)

3.Immunology 2020, Travel Grant , AAI ($1500)